Phase 3 Myasthenia Gravis Inebilizumab Trial (MINT): Minimal Symptom Expression Achievement with Inebilizumab
Richard Nowak1, Michael Benatar2, Emma Ciafaloni3, M. Isabel Leite4, Kimiaki Utsugisawa5, John Vissing6, Sarah Bray7, Blanca Canales8, Kristina Patterson8, Catherine Najem8, Sue Cheng8, James Howard9
1Yale University, New Haven, CT, USA, 2University of Miami Miller School of Medicine, Miami, FL, USA, 3University of Rochester, Rochester, NY, USA, 4University of Oxford, Oxford, UK, 5Hanamaki General Hospital, Hanamaki, Japan, 6University of Copenhagen, Copenhagen, Denmark, 7Amgen Ltd., 8Amgen Inc., Thousand Oaks, CA, USA, 9University of North Carolina, Chapel Hill, NC, USA
Objective:
To determine the proportion of MINT participants who achieved minimal symptom expression (MSE) with inebilizumab.
Background:
Inebilizumab’s efficacy in generalized myasthenia gravis (gMG) was demonstrated in MINT, which met its primary endpoint (change from baseline in Myasthenia Gravis Activities of Daily Living [MG-ADL] score).
Design/Methods:
MINT (NCT04524273) enrolled participants with anti-acetylcholine receptor antibody-positive (AChR+; n=190) or anti-muscle-specific kinase antibody-positive (MuSK+; n=48) gMG who underwent a protocol-specified steroid taper and were randomized 1:1 to inebilizumab or placebo for 26 (MuSK+) or 52 (AChR+) weeks (Ws) (randomized controlled phase). The proportion of participants who achieved MSE (MG-ADL score 0 or 1) without rescue therapy (RT) and those who achieved ≥3-point improvements in MG-ADL or Quantitative MG (QMG) scores were examined.
Results:
A greater proportion of participants receiving inebilizumab vs placebo achieved MSE without RT at W26 (combined, 29% vs 20%; AChR+, 27% vs 20%; MuSK+, 38% vs 17%) and W52 (AChR+, 46% vs 25%). Higher proportion of participants achieved ≥3-point improvements in MG-ADL scores without RT in the inebilizumab vs placebo group at W26 (combined, 69% vs 48%; AChR+, 68% vs 49%; MuSK+, 71% vs 46%) and W52 (AChR+, 72% vs 45%). Higher proportion of inebilizumab-treated participants achieved ≥3-point improvements in QMG scores without RT vs placebo at W26 (combined, 60% vs 41%; AChR+, 61% vs 40%; MuSK+, 57% vs 46%) and W52 (AChR+, 69% vs 42%). Data from the open-label phase will also be reported.
Conclusions:
Inebilizumab is associated with notable improvements in disease severity and function in patients with gMG.
Generative AI Usage
No, did not use generative AI in the drafting or editing in this abstract.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.